IRTC IRhythm Technologies Inc.

iRhythm Technologies to Report Third Quarter 2022 Financial Results on November 1, 2022

iRhythm Technologies to Report Third Quarter 2022 Financial Results on November 1, 2022

SAN FRANCISCO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2022 after the close of trading on Tuesday, November 1, 2022. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the investors section of the Company’s website at .

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Relations Contact

Stephanie Zhadkevich

(919) 452-5430

iRhythm Media Contact

Morgan Mathis

(310) 528-6306



EN
20/10/2022

Underlying

IRTCIRhythm Technologies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

Free Trial
IRTC IRhythm Technol...

Irhythm Technologies Inc: 1 director

A director at Irhythm Technologies Inc sold 8,000 shares at 207.440USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

IRTC IRHYTHM TECHNOLOGIES INC.
58m 58m 1 EN
 PRESS RELEASE
Free
IRTC IRhythm Technol...

iRhythm Technologies Announces Third Quarter 2025 Financial Results

iRhythm Technologies Announces Third Quarter 2025 Financial Results SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $192.9 million, a 30.7% increase compared to third quarter 2024Gross margin of 71.1%, a 230-basis point increase compared to third quarter 2024Unrestricted cash, cash equivalents, and...

October 30, 2025 1 EN
 PRESS RELEASE
Free
IRTC IRhythm Technol...

iRhythm Technologies to Report Third Quarter 2025 Financial Results on...

iRhythm Technologies to Report Third Quarter 2025 Financial Results on October 30, 2025 SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, October 30, 2025. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the con...

October 16, 2025 1 EN
 PRESS RELEASE
Free
IRTC IRhythm Technol...

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial ...

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA).AMALFI tested whether home-based, self-applied use of iRhythm’s Zio long-term continuous monitoring (LTCM) device and service could improve diagnosis of atrial fibrillation (AFib) in 5040 participants in the United ...

August 29, 2025 1 EN
 PRESS RELEASE
Free
IRTC IRhythm Technol...

iRhythm Technologies to Participate in Upcoming Investor Conferences

iRhythm Technologies to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time)Morgan Stanley Global Healthcare Conference 2025 on Tuesday, September 9, 2025, at 2:35 p.m. Eastern Time (11:35 a...

August 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch